Does TECLISTAMAB-CQYV Cause Disease progression? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Disease progression have been filed in association with TECLISTAMAB-CQYV. This represents 1.1% of all adverse event reports for TECLISTAMAB-CQYV.
18
Reports of Disease progression with TECLISTAMAB-CQYV
1.1%
of all TECLISTAMAB-CQYV reports
5
Deaths
2
Hospitalizations
How Dangerous Is Disease progression From TECLISTAMAB-CQYV?
Of the 18 reports, 5 (27.8%) resulted in death, 2 (11.1%) required hospitalization.
Is Disease progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB-CQYV Cause?
Cytokine release syndrome (406)
Immune effector cell-associated neurotoxicity syndrome (153)
Off label use (122)
Death (116)
Plasma cell myeloma (96)
Infection (83)
Neutropenia (74)
Fatigue (72)
Pyrexia (67)
Covid-19 (64)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which TECLISTAMAB-CQYV Alternatives Have Lower Disease progression Risk?
TECLISTAMAB-CQYV vs TEDIZOLID
TECLISTAMAB-CQYV vs TEDUGLUTIDE
TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER
TECLISTAMAB-CQYV vs TEGAFUR
TECLISTAMAB-CQYV vs TEGAFUR\URACIL